<DOC>
	<DOC>NCT01370980</DOC>
	<brief_summary>The purpose of this study is to implement a support interdisciplinary program(oncologists, pharmacists, physicians, nurses, leagues against cancer) of medication adherence to oral oncology treatments. The aim is to ensure continuity of care between professionals,effectiveness of treatment and patient safety.</brief_summary>
	<brief_title>Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment</brief_title>
	<detailed_description>80 patients will be included in swiss-romande hospitals and private oncologists and followed by thirty study pharmacies. Each refusal and drop-out will be documented. Follow-up duration is 48 weeks, with a motivational interviewing at least every three months. Patient adherence will be assessed electronically by MEMS (Medication Event Monitoring System).</detailed_description>
	<mesh_term>Mouth Neoplasms</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>18 years and older Treated for a cancer with oral medication (letrozol, exemestan,imatinib, sunitinib, nilotinib, everolimus, deferasirox) French speaking None</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Medication Adherence</keyword>
	<keyword>Patient Compliance</keyword>
	<keyword>Patient Acceptance of Health Care</keyword>
	<keyword>Administration, Oral</keyword>
	<keyword>Cancer</keyword>
	<keyword>Letrozol</keyword>
	<keyword>Exemestan</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Nilotinib</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Deferasirox</keyword>
</DOC>